Would UK approval of lecanemab be a game changer for people with Alzheimer's disease?
The Pharmaceutical Journal from the Royal Pharmaceutical Society
Source: pharmaceutical-journal.com
📰 Access Pathway News
Page 7 - Access Pathway News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Access Pathway. Real-time updates on events, politics, business and more.
EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023
/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its...
Source: prnewswire.com
FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease (1)
STOCKHOLM, July 7, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...
Source: europapress.es
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
Source: prnewswire.com
FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
07.07.2023 - The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare ...
Source: wallstreet-online.de
FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease (3)
STOCKHOLM, July 7, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...
Source: europapress.es
FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease (2)
STOCKHOLM, July 7, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...
Source: europapress.es
FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease
/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration, FDA, has approved...
Source: prnewswire.com
American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
LONDON, July 06, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to…
Source: sina.com.hk
COMPASS Pathways : Secures Term Loan Facility for Up to $50 Million from Hercules Capital
COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital London, UK - July 5, 2023 COMPASS...
City Of United Kingdom Morrison Foerster Bryan Jadot Kabir Nath Life Sciences Group Head At Hercules Capital
Source: marketscreener.com